Volume 24, Number 1Prostate CancerDarolutamide for Metastatic Hormone-Sensitive Prostate Cancer: An Overview of Meta-Analyses and Indirect Treatment ComparisonsNeal D ShoreAlicia K. MorgansNoman ParachaSarah HodgkinsonChristian S. EichingerCraig MillarStephanie ChenHoward ThomMartin BoegemannWe evaluated the numerous published indirect treatment comparisons (ITCs) and meta-analyses of the efficacy and safety of treatments in metastatic hormone-sensitive prostate cancer (mHSPC), which include the ARASENS study of darolutamide triple therapy, to identify limitations of the evidence and to suggest methodological improvements.network meta-analysisoverall survivaladverse eventsProstatic neoplasms